Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Diversification is Good!
In my view, Karim is setting the stage for a buyout and higher price.
He is basically saying Vascepa has other potential applications besides cardio benefits, but Amrn does not have the resources or time to develop these applications. Big Pharma does and these potential applications justify paying a higher price!
Stay tuned!
Kennedy lived in San Francisco, was lazy, do not like travel and essentially sold every stock option granted asap. His decision, for convenience, to try this case in Nevada with a liberal unqualifed judge with limited patent experience was a colosal mistake and Amarins previous high priced attorney's did a lousy job. In additon to Kennedy & Thero, the entire board should be fired for complacency and negligence on this very costly error. With the new attorneys, I have hope!!
Yesterday Decline.
In large part was caused by Fidelity issuing an "exacerbated margin call for any client who held Amarin shares on margin. Usually, a client has 4-5 days to cover a margin call. Not sure what prompted Fidelity's abrupt decision over the weekend to eliminate all margin debt on Amarin stock as the stock is not a speculative bubble like Gamestop. From past experience, Fidelity can be very arbitrary and abrupt on margin calls- more so than other brokers. Not sure what other brokerage firms did if anything. The only slight positive is there is no overhang today. All the margins positions were closed out yesterday. Yes, I will be moving my account to another firm. Any suggestions as at these prices, I would like to buy more!
Great Post CaptBeer! - My pick Novartis-Here are the reasons why!
Novartis has $48B in sales,$9B in cash,$11B in cash flow, but only 3% growth
Cardio is a major product line for Novartis
They have a division Sandoz, a generic drug maker and producer of biosimliars
Biosimiliars are drugs made out of natural ingredients, not chemicals.
Vascepa is a made out of a natural product - fish oil.
Novartis is based in Switzerland, very stong in Europe where they can ramp up sales very quickly and strong in China and ROW(Rest of World)
Over time, Novartis/Sanodz/Amarin can bring the manufacturing in house and improve margins
Narasimhan & Breadner, the CEO & President both spent time in Boston/Harvard and I am confident they know and respect Dr Bhlatt- Amarin's top medical advisor.
Narasimhan is a CEO who wants to develop and market drugs worldwide that improve mankind.Vascepa meets that need.
Novartis has been criticized for developing a specialty drug that costs $2M annually. Vascepa offsets that criticism.
The change of control, expedited vesting of stock options for the executives lose a lot of value if Biden's potential increased capital gains tax rates to 39% go into effect.
My sense is the offer will come when the European Approval is official within 30- 60 days.
In a nutshell, the stars are aligned- the retail investors, Mgt, Baker Brothers and other institutional investors are ready to put this property in the hands of Big Pharma and move on.
Stay tuned!
ILoveTech
I hope you are right on the BO Price!! But $20 looks pretty good right now and this is a one trick pony with with patent protection for less than 9 years. The interim report tomorrow should give the stock a decent bounce tomorrow.
Stay Long & Stay Strong!
The last few months have been disappointing for "members of the fish oil nation." However, I am cautiously optimistic the future is brighter. Here are the reasons why-
The are 7 members of the Board of Directors and only two are Amarin Mgt-
Thero & the former CEO Zakrewski. The Executive Chair is Lars Eckman, a partner with Sofinnova Ventures which owns 5 M shares now worth $33M and were worth $120M less than a year ago! Although he lives in La Jolla Ca, he and two other directors have extensive European Big Pharma contacts and all directors have extensive Big Pharma contacts and history.Formally or informally, discussions are going on. Officers own another 3.5M shares and have options on another 20M+ shares.
Bottom line, between Soffinova,other institutional investors, and the mgt, there is significant pressure to get the price up and cash out via a sale once the lawsuit is settled by year end. GIA is not a viable business option. and the long term investors like Soffinova want to cash out as do many individual investors and move on. Keep in mind, this lawsuit is only for the right to sell the generic version to patients with triglycerides above 500 mg which is only 10% of the US Market. There are some who feel if the generics win the lawsuit, they will sell to the entire market one way or the other. I agree with MGT, Amarin can legally stop that event by suing CVS, Walgreens etc., who are not inclined to break the law and the same goes for the big Health care companies. Companies do not like the threat of treble damage lawsuits.
On the negative side, mgt and directors have received and sold stock options of approximately $150M over the past three years- mostly around the $20 level.The biggest seller has been the legal VP Kennedy who has sold approximately $30M, owns very few shares and should have been fired for the disastrous legal strategy and outcome. In hindsight, the "fish oil nation" should have picked up on Kennedy's sales sooner. My sense is the buyout price will come in around $20 per share where mgt and directors were previously selling shares and where GS priced the offering.
Stay tuned!
Postes
I think JL is right here. If a cardiologist prescribes Vascepa and the pharmacist fills the prescription with a generic, that is a patent violation and Amarin will sue.There are only 5-10 major pharmacy chains in the the US-CVS, Walgreens, Walmart, Duane Reade, etc. Easy for the Amarin legal team to sue for treble damages and these large publicly owned pharmacies will not engage in this illegal, unethical behavior.
MASSULO 52 & Others
I respect your opinion, but if what you say is true, there is no way to track the distribution why have not the generics already started doing it ? They have the patent for above 500mg? We live in the most litigious society in the world. Amarin and their largest shareholder Baker Brothers would easily spend $10m plus to stop and sue for treble damages . Gotta go, still have a day job!
I did read Pharma dudes posts and agree, phrarmcies will go with the cheaper drug above 500mg . Amarin will sue the distributors and pharmacies and win if they prescribe the generics for patients between 150 -500 mgs where Amarin patents are rock solid.
The patent case the generics won was for patients with trigs above 500 Mgs not the reduce it patent which was granted almost 2 years ago for patients with trigs between 150 -500. This patent still stands, was not contested and is very strong.
The patent the generics challenged and won was for the patent above 500 mg of triglycerides which is only 10% of the market. This is the patent Amarin has before r the Reduce It study . The stock was then selling for around $4 Because it was only 10% of the patients .
Angla
True, but the generics would only have 10% 0f the US Market assuming they win
Stay Long and Strong!
It has been a while and like everybody, I am disappointed and shocked by Judge Du's decision which I believe will be overturned. What truly baffles is the sharp decline in the stock price. Even if the generics prevail on the appeal, they only have the right to sell the drug to patients with triglycerides of 500mg or higher which is only 10% of the market and Vascepa is a difficult drug to manufacture, drug distributors, pharmacies and Md's would prefer to prescibe/ stock one drug they can prescribe for patients above and below 500mg and if necessary, Amarin could come out with a generic brand for 500mg and above. Generics like to attack a drug that is high priced, high volume and easy to make. Vascepa is a low cost and difficult drug to make and the supply source is constrained.To me, even if Amarin loses the appeal, they still have 90% of the US market, all of Europe, and more! The stock should be @$15-20 per share. Moderna which has no approved drugs and a possible vaccine for COVID 19( among several other firms trying) has a market cap of $25B- that's right- Billion!! Amarin has $800M in sales and a market cap of less than $3B. What am I missing here???
STAY LONG & STAY STRONG!
For what it is worth,I sat next to and chatted with the Citi Analyst-Joel Beatty 18 months ago when Amarin announced the positive Vascepa results at the Chicago AMA Conference. He had a very conservative, cautious outlook on Amarin, came across as a very thoughtful analyst with a relatively low price target.
The fact that Beatty is now far more positive on Amarin is significant. And his price target is based upon internal growth not a buyout which many believe will happen by the end of the year. Additionally, Cardiology Today and the European Heart Association Magazine both published very favorable articles over the past few days.
Stay tuned!
Stay Long & Strong!
I have not posted in a while,but here are my thoughts on the Baker Brothers Stock Sale in Q4/19:
Institutions bought 12M plus more shares than they sold.
Artisan Partners increased the holdings by 3M+/- shares and now hold almost 16M shares- second I believe to BB.
BB sold enough shares to get just under 10% which reduces SEC reporting
and frees up cash for them to invest in other startups at $1+/- a share where BB has done very well as long term investors.
Amgen just had a massive multi billion dollar shelf registration and there is some speculation they may make an offer - uncontested or contested once the judge issues an opinion.
Both Jeffries and Cantor Fitzgerald who have followed the stock and trial closely have maintained their positive price targets of $30 & $35 per share.Almost all other Big Pharma Co's are struggling with flat, declining sales and weak pipelines. I expect a buyout by end of year in the $30-35 range. Ideally, it would an be a tax free exchange of stock with a Big Pharma paying a 3% dividend. Stay Tuned!
STAY LONG & STAY STRONG!
Although it does not mention Vascepa by name, a pretty good article on page B3 of the WSJ today. In essence, it mentions a lot of these heart drugs like Repatha, Prualuent and Entresto have not done that well as they are only marginally effective and expensive Consequently, the insurance companies are resisting coverage with higher co-pays and more paperwork. Additionally 2 of the drugs are self injected which is less desirable than taking a Vascepa pill. Insurers will encourage patients to try the much less expensive and more effective alternative first. Price action should be pretty good next week as we get closer to FDA Approval.
Stay tuned!
Stay Long & Stay Strong!
I have not posted in a while, the day job keeps getting in the way! However,I greatly appreciate all the effort Jesse, Sam 81,BB and others have put into this community website. My brother and I own just under 2M shares which we bought @ an average cost of $2.00+/-. So we do follow "fish oil' quite closely! I see the key metrics as follows:
Growth-
Thero mentioned the US Patient population @15M+/-. If Amarin gets 20% with annual revenue per prescription of $1,500 that equals $4.5B in the US alone.Scripts have been going up weekly and hit an all time high the week after ADCOM with new prescriptions showing the highest increase. I agree with the analyst from Cantor Fitzgerald Louise Chen, the sales potential of Vascepa is under appreciated.
Label Expansion
Given the Reduce IT Study, the ADA & AHA endorsements and the Adcom 16-0 vote in favor of Vascepa, the label expansion is a given. There may be some tweaking whether the level is 135 or 150. Secondary will be given and primary will be given for any patient who has one or more symptoms of Cardio problems.
Patent Protection
I do not see this as a big issue. Amarin has 80-90 patents and only a couple are being contested. The judge has ruled in Amarin's favor on some, not all preliminary motions. However, this is a very low cost drug and difficult to make. Generics are a threat to drugs that sell for $10K per month and a generic comes on the market for $2K per month.
Market Strategy
Amarin's Plan is to make this a consumer product once label expansion is received with heavy media and print advertising and a sales force of 800 to create a first to market dominant position. It has taken a long time and a lot of money to educate the MD's & Cardiologists on the advantages of Vascepa as well as $1B in R&D. The MD's are cautious, and will be reluctant to go with a knockoff to save a few bucks for insurance companies.
Supply Chain
This is a difficult drug to make and Amarin has locked up most of the suppliers with long term contracts
Outlook/Risks
The Bulls say this will be one of the best all time drugs up there with Lipitor @$10B in annual revenue. The risks are:
Can Amarin develop the Supply chain to meet this $10B demand?
How quickly can Amarin ramp up the Sales?
Can another drug company reverse engineer Vascepa and come up with a similar product like Tyelenol and Aleve or Viagra,Cialis or Levitra?
I agree with Louise Chen & Cantor Fitzgerald - the BO offers will come in around $35 from Big Pharma who need Vascepa to replenish their pipelines. Amgen & Gilead are the leading contenders. Ideally, it would be a cash or stock exchange deal where we could receive a stock paying a dividend, diversify and avoid 25-30% in capital gains taxes depending where you live.
Stay tuned!
Test
Stay Long & Stay Strong!
Here are my thoughts on the last 3 weeks.
Amarin has been in active discussions with Big Pharma about selling. Prices were coming in around $25+/- per share. Goldman,JP Morgan,Baker Brothers told Amarin if you can increase sales from:
$228 12/23/18
$400M 12/31/19
$1B 12/31/20
We can get closer to $40+/- per share and a $1B company with this kind of growth is more attractive to Big Pharma and they will pay a higher premium. To achieve this goal, Amarin needs to get FDA approval, expand the sales force and buy/build a manufacturing plant to meet the higher demand and bringing some of the mfgr in house will increase margins.Keep in mind, to become a $5B company, Amarin needs to demonstrate to potential buyers they can create a supply chain to meet the demand and this is not an easy product to make. Amarin Mgt basically agreed with the Plan and with the caveat if a better offer comes, we will consider it but we can GIA with the $400M cash raise which strengthens their negotiating position.
My view was the FDA was planning to waive the Adcom approval until the Novartis debacle happened two weeks ago where they were falsifying data. The FDA then took the position we want every applicant to get Adcom approval which provides independent substantiation of the claims,does not take that long and provides cover for the FDA. This is the reason for the late and sudden Adcom requirement, not the
backlog. On the plus side the Adcom has 5 endocrinologists and 3 cardiologists. To me, this indicates the language on heart issues is a settled matter. The open issue is the extent of the language on diabetes.
Bottom line , I agree with the other 6 analysts who cover this stock for a living- this is a buying opportunity!!!
Stay Long & Stay Strong! Here are the reasons why!
Clearly, the FDA was negligent not announcing the Adcom requirement a month or two ago whether they were understaffed or backlogged given the blockbuster potential of Vascepa. Amarin should have received priority over lower profile drugs. On the plus side,I see a positive approval for the following reasons
Vascepa has been approved by the FDA for over 5 years for patients with triglycerides over 500, has been effective and no side effects
The Reduce It Study showed a 25% reduction in coronary issues
The AHA has endorsed Vascepa as a standard of care treatment
The ADA has endorsed Vascepa as a standard of care treatment.
The preliminary ICER study was positive
With recent Q2 sales of $100M plus, MD's and patients see the value.
What is an Adcom?
An Adcom is an Advisory Committee of 15-20 members appointed by the FDA to review the existing documentation and advise whether the representations are valid. The FDA is not obligated to take their advice.The FDA made the decision to go forward with the Adcom for two reasons.
The Blockbuster nature of Vascepa. Adcom confirms and validates their decision to approve.
The language on the label. Adcom provides confirming support for the langauge on the label. Example -does the language say Vascepa is effectve for patients with triglycerides above 125 or 115? Amarin is pushing for the most expansive label possible and Adcom gives the FDA cover they did their due diligence.
Keep in mind, Amarin was expecting an Adcom Review up until a couple weeks ago and is well prepared with the data above and much, much more!
If the spirit move you, check out post 207801 by sharinky on a drug Victoza approved by an Adcom on 2 votes 19-0 & 17-2. The key metric for an Adcom Committee is- Does the drug have substantial independent evidence to support it claim? Victoza btw had serious potential side effects that it was required to disclosed including thyroid cancer, shortness of breath and swelling. Conversely, Amarin has negligible side effects and a substantial amount of independent evidence validating the benefits. Last but not least, my sources tell me the Adcom Committee members are more endocrinologists- diabetes than cardiologists indicating the discussion is more about the language on diabetes. The language on heart issues is more or less settled.
Stay tuned!
Stay Long &Stay Strong! Here are the reasons why!
Baker Brothers & Amarin Mgt. are of the opinion Vascepa could be the best selling drug of all time- low cost, world wide market , once an MD prescribes, the patient will take for the rest of their lives. And unlike Lipitor,Vascepa has negligible side effects.
The $400M. Equity is to do the following: build inventory, possibly buy or build a mfg plant, add 400 sales reps and start a massive consumer advertising campaign . However, Amarin can not commence advertising until the FDA Office of Prescription Drug Promotion approves the advertising copy. This process takes 5-6 months after FDA approval.
With 800 reps and consumer advertising, Sales could easily reach $1B for 12/31/20 & $2B for 12/31/21 with European approval which will happen in the next 6-9 months . My sense a 25% chance of a buyout this fall under $35 and a 75% chance of a buyout within 2 years between $35-50. There were 3-4 biotech stocks , Array being one of them that were bought out within 120 days of a public offering. What I do not understand is why the stock price has not received more support from Goldman &JP Morgan. That is their job as underwriters and market makers!
Stay Long and Stay Strong, the Best is yet to Come!
Stay Long & Strong- Here are the reasons why!
The Reduce Study was a great success
Recommended as a standard of care by AHA
Recommended as a standard of care by ADA
The ICER Report was very positive
Adcom will not happen
FDA approval is a given
Patents are not an issue per Jeffries analyst
Baker Brothers has not sold a single shares
Yes,some of the Execs have sold some shares, but none have left, the best is yet to come and they all have substantial options
Goldman & JP Morgan researched this deal carefully and did not do the offering unless they saw great upside potential. They also did the offering to give Amarin bargaining power with Big Pharma- we have the cash to GIA
3 biotechs- Array, Enodycte & Avexis all did public offerings and were bought out by Pfizer and Novartis within 90 days.
My prediction, Amarin gets an offer around $35 by year end or they GIA, hire the sales reps, buy or build a plant, get the sale up to $1B plus and sell for $50 per share within 2 years. Most likely buyers-Novartis or Amgen.
Vascepa has a great profile, low cost, difficult to make, world wide market and any MD who does not recommend Vascepa to a patient with high triglycerides is subject to a lawsuit for negligence if the patient has a stroke.
Stay tuned!
Stay Long & Strong! Here are the reasons why!
Lets try this again-Stay Long & Stay Strong-Here are the reasons why
Stay Long & Stay Strong! Here are the reasons why-
A Long Term Positive !!
Last but not least, I see this as a $50-100 stock within 3 years as they scale up to sell to Big Pharma. And I think Goldman, JP Morgan and Baker Brothers have the same opinion.
A Long Term Positive!!
My Takeaways as follows.
Amarin will use the cash to hire sales reps and most importantly expand mfg capacity by building plants or buy out an existng supplier which ultimately will increase profitability and growth
FDA approval is certain.
The fact Goldman and JP Morgan have researched Vascepa and are underwriting the deal validates the fact this is a blockbuster drug and lends credence to those who say Vascepa could be one of the all time best selling drugs.
And I am sure Baker Brothers agrees ans support the Plan.
Steady Climb Up!!
Here are the Reasons Why-
Amarin gets FDA Approval mid September or sooner.
Upon approval, Amarin launches an advertising blitz which presently they can not do without restrictions
Renewed and stronger endorsements from the AHA & ADA among others that Vascepa should be the standard of care for patients with mid to high triglycerides.
These endorsements are re-enforced by the lawyers that given the low cost and effectiveness, not recommending Vascepa to patients with mid to high triglycerides will result in lawsuits for medical negligence!
Amgen and Novartis are in my opinion, the two leading candidates for the BO. Amgen has a heart drug Repatha which is expensive, does not work that well and has to be injected. The new President of Novartis is of Indian descent as is Dr Bhatt of Amarin and they both know each other and spent time at Harvard. There are other Big Pharma's that are possible, but these two are focusing more on cardio and the others on cancer cures.
Stay tuned!
AMRN to AMGN
Thero did a very good job presenting and clearly, based upon the steady price climb upwards today, some of the institutional investors increasing positions thought so as well. Not sure what was covered in the Q&A , but the transcript of his speech was compelling and in my opinion geared to the Big Pharma potential buyers once final approval is received in September. My prediction is still Amgen and btw Thero is presenting at the Goldman Sachs Health Care Conference in Rancho Palos Calif- once again close to Amgen's HQ in Thousand Oaks. Also nice to see Amarin building support here with presentations @ Cantor Fitzgerald, Jeffries and Goldman all within a couple of weeks.
Stay tuned!
AMRN TO BECOME AMGN!!
My apologies I meant to post this yesterday but my day job got in the way!
Sequence as follows:
AMRN is making presentations in Denver and SF hosted by Joyce Chen , lead analyst and Cantor Fitzgerald their lead investment bank. My opinion,after the SF conference , Thero and CF will meet with AMGN and negotiate term, conditions and timing. AMGN is HQ in Thousand Oaks, Calif.
Within 2 weeks, maybe sooner( yes Indeed!) AMRN will receive Priority Review and Chen will re-iterate her $35 price target, possibly higher.
Both AMRN & AMGN are Platinum Sponsors at the EAS(European Atherosclerosis Conference in the Netherlands May 28/29. No other Big Pharma Platinum Sponsors. AMRN needs a European Partner with a sales force.
AMGN has $26B of cash/securities and $11B of annual cash flow.
AMGN's top drugs are losing steam- down $500M- see Motley Fool article published a couple of days ago.AMGN sales have been flat the past 3
years. CEO's get paid to increase revenue and shareholder value.
Vascepa is a product that has been recommended by the AHA/ADA as a standard of care,is low cost, difficult to produce, has a world wide market and good patent protection.
My only issue is timing whether the Baker Brother hold out for top, top $ after the official approval is received. Stay tuned!
test
Buyout will happen in the fall. Here are the reasons why. To get the maximum value,Big Pharma has to know precisely what the final FDA approved language will be on the SNDA. Amrn is building inventory so when Big Phamrma makes an offer in the fall they can can justify a higher price to their BOD that potential revenue in 2020 can be $750M plus with the increased inventory and sales force expansion. Amrn has not and will not sign any deals with European Partners as they do not have the inventory and do not want a burdensome long term agreement. Most likely buyer is Amgen for the following reasons: they have $20B in cash, their heart drug Repatha is expensive and has to be injected as opposed to Vascepa which is inexpensive and orally consumed. Big Pharma Companies want to build their portfolios around cancer and heart drugs, the two largest markets. Cantor,Jeffries,HC Wainright have all made their $30-50 price targets based upon a 12 month time frame- ie late fall. Baker Brothers and Amarin Mgt are talented,know what they are doing and will be ready to cash out by the end of the year. My sense - $35+/- per share.Stay tuned!
Here is my read on the offering
1 Amrn submits sNDA Q1/19 and most likely receives formal approval in Q3/19. Big Pharma's position is we do not want to make our best and final offer until FDA officially approves.
2.As of 9-30 Amarin had $30M of short term and $83M of long term debt-$113M total and $81M of cash.After this offering, total cash will be $281M. However, in a complicated deal a few years back,Amrn sold the Vascepa patents to Pharmakon for $100M=/- with the right to buy them back for $150M+/- and I believe some payments have been made. This offering will give them the cash to buy back the patents which Big Pharma would insist upon prior to paying $15B+/-.
3. Amrn may well use some of the money to buy or build a mfr plant which will improve the margins and enhance the value to Big Pharma.
4. Two underwriters should add stability and support to the stock price once the secondary is complete.
5. This transaction would not be done without the support and approval of Baker Brothers-their largest shareholder and a successful fund focused on biotechs.
6. Bottom line, the buyout may be delayed a year, but the price will be higher. Agreed,Thero is not a charismatic sales guy, but he is a talented biotech exec.
Stay tuned
Here is my read on the offering.
1.
MY PREDICTION - SORRY GUYS AND GALS - STICKY FINGERS! HERE ARE THE REASONS: THERO IS A SMART GUY(TALKED WITH HIM AT THE AHA CONF) AND IS SETTING UP A BIDDING CONTEST BETWEEN AMGEN AND ASTRA ZENECA. HE IS HIRING 400 SALES REPS IN THE US BECAUSE THE DEAL WITH KOWA EXPIRES SOON. THERO IS TALKING ABOUT A PARTNERSHIP WITH A EUROPEAN BIG PHARMA AS A PLOY THAT AMRN CAN GO IT "ALONE" WHAT ABOUT SOUTH AMERICA ,ASIA? WHAT ABOUT MGR & LEGAL COSTS THAT BIG PHARMA CAN BRING IN HOUSE AND HAS THE SCALE TO EXPAND THE SALES PIPELINE RAPIDLY? THESE EXECS HAVE BEEN WORKING 5-10 YEARS AND HAVE DONE A GREAT JOB AND IN MY OPINION ARE READY TO CASH OUT. WHAT ABOUT THE BAKER BROTHER WHO OWN 40M SHARES FOR THEIR CLIENTS AND THE "BOSTON BROTHERS" WHO OWN 2M SHARES PERSONALLY? THESE AND OTHER FINANCIAL HOLDERS WILL PRESSURE THERO TO SELL IN THE NEXT 90 DAYS. AND THE PATENTS ONLY LAST TEN YEARS!
MY PREDICTION IS AMGEN FOR THE FOLLOWING REASON:
THEY HAVE A HEART DRUG REPATHA THAT IS NOT DOING THAT WELL.SALES ARE STAGNATING AT $20B+/- OVER THE PAST 3 YEARS. MOST IMPORTANTLY THEY HAVE
$41B IN CASH AND MKT SECURITIES. AMGEN COULD PAY $40 PER SHARE($12B) AND STILL HAVE ABOUT $29B LEFT AND FIX THEIR PIPELINE AND GROWTH ISSUES. ASTRA ZENECA NEEDS VASCEPA TO SUPPLEMENT ESPANVOA BUT DOES NOT HAVE THE CASH -$4.5B - POSSIBLE BUT NOT LIKELY.
STAY TUNED!
MY PREDICTION!
FIRS AND FOREMOST, WE HAVE A LOT TO BE THANKFUL FOR! HAPPY THANKSGIVING TO ALL AMARIN LONGS! A SPECIAL THANKS TO JESSE AND ALL THE OTHERS WHO KNOW THE MEDICAL STUFF BETTER THAN I DO. MY PREDICTION IS AMARIN WILL BE BOUGHT BY ASTRA ZENACA OR AMGEN IN Q1/19 FOR $40+/- PER SHARE FOR THE FOLLOWING REASONS-
'
Jesse Thanks for coming back to the Board! I am sorry we did not connect at the AHA Conference. My takeaways as follows; I attended both sessions and actually sat next to Joel Beatty the citibank analyst at the evening investor conference. Very knowledgeable, nice guy. Also spent time at the Amarin booth. The Sales Team is talented, experienced and pumped up! Since Sunday:
Cantor Fitzgerald has re-affirmed their $35 target.
HC Wainright has raised their target to $51.
Citibank has announced today a $28 target
John Thero will speak at the Jeffries Health Care Conference in London tomorrow and I expect Jeffries will re-affirm or increase their price target as well. Keep in mind, these analysts are professionals, talented and all make $1M plus. They have dismissed the mineral oil issue and the Pomerantz bogus investigation. Yet since Sunday the price has gone down from 22 to 15?
As an investor,the fundamentals and potential are strong and very promising . I do not understand the mentality of the traders. Markets at times are irrational.
Session just ended. I was sitting next to a phama sales rep and md and asked what their impressions were of the presentation. The responses were convincing and impressive! Monday will be a positive day. Happy to wait outside the conf area and met and greet any other amarrinites! Blue sweater, yellow shirt and iPad .
Pardon the misprints, small type.
Bfost. Let's connect after the presentation. I will wait in the back. Wearing blue v neck sweater and yellow shirt
Confident, knowledgeable and ready to go Monday morning. Mandatory cc tomorrow.